D. Cignoli, G. Fallara, C. Re, F. Cei, G. Musso, G. Basile, G. Rosiello, A. Salonia, A. Larcher, F. Montorsi, U. Capitanio
BACKGROUND: The influence of age and comorbidities during decision-making for patients with renal cell carcinoma remains controversial. OBJECTIVE: To comprehensively review the available evidence regarding the impacts of age and comorbidities on the decision to perform partial nephrectomy (PN). EVIDENCE ACQUISITION: A systematic review was conducted in accordance with PRISMA and registered with PROSPERO (CRD42022344759). Only randomized control trials, prospective cohort studies, registry-based studies, or single/multi-institutional retrospective cohort studies comparing PN to other therapeutic options for cT1N0M0 renal masses were considered. The primary outcome was to assess differences in patients’ baseline characteristics between different treatments in order to investigate how those aspects have influenced clinical decision-making. Finally, perioperative outcomes were compared across the different options. EVIDENCE SYNTHESIS: Overall, patients who underwent PN were 3 to 11 years younger than those who underwent other treatments. Baseline renal function was slightly better in patients who underwent PN than in those who underwent radical nephrectomy (RN), active surveillance (AS), or tumor ablation. Patients undergoing PN had an average pre-treatment eGFR 4 to 6 points (mL/min/1.73 m2) higher than patients undergoing RN or tumor ablation. Likewise, the proportion of baseline chronic kidney disease (CKD) before treatment was higher in patients undergoing other treatments, with a rate of CKD between 6% and 56% higher compared with that for PN. A slightly higher proportion of baseline diabetes mellitus (DM) and cardiovascular comorbidities (CVD) were found in patients who underwent PN than in those who underwent RN (20% vs. 21% for DM and 37% vs. 41% for CVD). On average, patients who underwent AS and tumor ablation had more comorbidities, in terms of Charlson comorbidity index (CCI), DM, and CVD (50% vs. 38% for CCI ≥2; 25% vs. 20% for DM; and 43% vs. 37% for CVD). In terms of Eastern Cooperative Oncology Group (ECOG) Performance Status and American Society of Anesthesiologists (ASA) classification, no major differences were found between PN and other treatments, but a trend emerged whereby more fit patients underwent PN compared with RN (16% of ECOG >1 for PN vs. 18% for RN and 15% of ASA grade ≥3 for PN vs. 26% for RN). Again, tumor ablation was preferred for less fit patients (31% of ASA grade ≥3). No study included in our systematic review reported the baseline frailty status of patients treated for cT1 renal masses. The rates of perioperative complications and length of hospital stay (LOS) were similar between different techniques. CONCLUSIONS: Patients who underwent PN tended to be younger and fitter than those who underwent other available treatments for cT1 renal masses. Since this technique aims at reducing renal function impairment after surgery, a greater effort should be made to optimize patient selection to include more comorbid pat
背景:年龄和合并症对肾细胞癌患者决策的影响仍有争议。目的:全面回顾有关年龄和合并症对决定进行部分肾切除术(PN)的影响的现有证据。证据获取:根据PRISMA进行了系统评价，并在PROSPERO注册(CRD42022344759)。仅考虑随机对照试验、前瞻性队列研究、基于登记的研究或单/多机构回顾性队列研究，比较PN与cT1N0M0肾肿块的其他治疗方案。主要结果是评估不同治疗之间患者基线特征的差异，以调查这些方面如何影响临床决策。最后，比较不同方案的围手术期结果。证据综合:总体而言，接受PN治疗的患者比接受其他治疗的患者年轻3 - 11岁。接受肾切除术的患者的基线肾功能略好于接受根治性肾切除术(RN)、主动监测(AS)或肿瘤消融的患者。接受PN的患者治疗前eGFR平均比接受RN或肿瘤消融的患者高4 ~ 6个点(mL/min/1.73 m2)。同样，在接受其他治疗的患者中，治疗前基线慢性肾脏疾病(CKD)的比例更高，CKD的发生率比接受PN治疗的患者高6%至56%。在接受PN的患者中发现基线糖尿病(DM)和心血管合并症(CVD)的比例略高于接受RN的患者(20% vs 21% DM和37% vs 41% CVD)。平均而言，接受AS和肿瘤消融的患者在Charlson合并症指数(CCI)、DM和CVD方面有更多的合并症(CCI≥2的50% vs 38%;DM组25% vs 20%;43% vs. CVD 37%)。在东部肿瘤合作组(ECOG)的表现状况和美国麻醉医师协会(ASA)的分类方面，在PN和其他治疗之间没有发现重大差异，但出现了一种趋势，即与RN相比，更多适合的患者接受了PN(16%的ECOG患者接受了PN, 18%的患者接受了RN, 15%的患者接受了PN, ASA分级≥3的患者接受了PN, 26%的患者接受了RN)。同样，不太适合的患者首选肿瘤消融(31%的ASA分级≥3)。在我们的系统综述中，没有研究报告cT1肾肿块治疗患者的基线虚弱状态。不同技术的围手术期并发症发生率和住院时间(LOS)相似。结论:接受PN治疗的患者比接受其他治疗的cT1肾肿块的患者更年轻，更健康。由于这项技术的目的是减少术后肾功能损害，因此应该做出更大的努力来优化患者选择，以包括更多可能对PN有用的合并症患者。
{"title":"Influences of Age and Comorbidities on Indication for Partial Nephrectomy: A Systematic Review","authors":"D. Cignoli, G. Fallara, C. Re, F. Cei, G. Musso, G. Basile, G. Rosiello, A. Salonia, A. Larcher, F. Montorsi, U. Capitanio","doi":"10.3233/kca-230001","DOIUrl":"https://doi.org/10.3233/kca-230001","url":null,"abstract":"BACKGROUND: The influence of age and comorbidities during decision-making for patients with renal cell carcinoma remains controversial. OBJECTIVE: To comprehensively review the available evidence regarding the impacts of age and comorbidities on the decision to perform partial nephrectomy (PN). EVIDENCE ACQUISITION: A systematic review was conducted in accordance with PRISMA and registered with PROSPERO (CRD42022344759). Only randomized control trials, prospective cohort studies, registry-based studies, or single/multi-institutional retrospective cohort studies comparing PN to other therapeutic options for cT1N0M0 renal masses were considered. The primary outcome was to assess differences in patients’ baseline characteristics between different treatments in order to investigate how those aspects have influenced clinical decision-making. Finally, perioperative outcomes were compared across the different options. EVIDENCE SYNTHESIS: Overall, patients who underwent PN were 3 to 11 years younger than those who underwent other treatments. Baseline renal function was slightly better in patients who underwent PN than in those who underwent radical nephrectomy (RN), active surveillance (AS), or tumor ablation. Patients undergoing PN had an average pre-treatment eGFR 4 to 6 points (mL/min/1.73 m2) higher than patients undergoing RN or tumor ablation. Likewise, the proportion of baseline chronic kidney disease (CKD) before treatment was higher in patients undergoing other treatments, with a rate of CKD between 6% and 56% higher compared with that for PN. A slightly higher proportion of baseline diabetes mellitus (DM) and cardiovascular comorbidities (CVD) were found in patients who underwent PN than in those who underwent RN (20% vs. 21% for DM and 37% vs. 41% for CVD). On average, patients who underwent AS and tumor ablation had more comorbidities, in terms of Charlson comorbidity index (CCI), DM, and CVD (50% vs. 38% for CCI ≥2; 25% vs. 20% for DM; and 43% vs. 37% for CVD). In terms of Eastern Cooperative Oncology Group (ECOG) Performance Status and American Society of Anesthesiologists (ASA) classification, no major differences were found between PN and other treatments, but a trend emerged whereby more fit patients underwent PN compared with RN (16% of ECOG >1 for PN vs. 18% for RN and 15% of ASA grade ≥3 for PN vs. 26% for RN). Again, tumor ablation was preferred for less fit patients (31% of ASA grade ≥3). No study included in our systematic review reported the baseline frailty status of patients treated for cT1 renal masses. The rates of perioperative complications and length of hospital stay (LOS) were similar between different techniques. CONCLUSIONS: Patients who underwent PN tended to be younger and fitter than those who underwent other available treatments for cT1 renal masses. Since this technique aims at reducing renal function impairment after surgery, a greater effort should be made to optimize patient selection to include more comorbid pat","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":"1 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41645049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: The historical standard of care for locally advanced renal cell carcinoma (RCC) is nephrectomy + active surveillance. Despite a high recurrence rate ( 40% ), adjuvant therapy was previously not included in the standard of care. This review of adjuvant pharmacotherapy reflects conflicting results from multiple trials. OBJECTIVE: The objective of this review is to summarize the efficacy of therapy vs surveillance in resected early-stage intermediate to high-risk renal cell carcinoma. METHODS: We performed a systematic literature search using PubMed, EMBASE, and SCOPUS. Keywords such as “renal cell carcinoma”, “adjuvant therapy” and “nephrectomy” were used. In the literature search, 2,711 studies were identified and screened. RESULTS: We included a total of 21 publications. The most common histology seen in trials was clear cell carcinoma. A variety of interventions were reviewed including immunotherapy, medroxyprogesterone acetate, interferon alfa, and tyrosine kinase inhibitors. Most trials did not demonstrate a benefit in relapse-free survival (RPS) or overall survival (OS). Pembrolizumab demonstrated a significant difference in disease recurrence in the KEYNOTE-564 trial although median data was not reached. Blinded independent reviewers identified a benefit in disease-free survival (DFS) with Sunitinib in the S-TRAC trial. CONCLUSION: There was not a clear benefit in using adjuvant therapy broadly for resected locoregional RCC; however, further investigation should be done in the highest-risk group to elucidate potential benefit.
{"title":"Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma","authors":"C. Major, Carlos I. Rodriguez, N. Haas","doi":"10.3233/kca-220018","DOIUrl":"https://doi.org/10.3233/kca-220018","url":null,"abstract":"BACKGROUND: The historical standard of care for locally advanced renal cell carcinoma (RCC) is nephrectomy + active surveillance. Despite a high recurrence rate ( 40% ), adjuvant therapy was previously not included in the standard of care. This review of adjuvant pharmacotherapy reflects conflicting results from multiple trials. OBJECTIVE: The objective of this review is to summarize the efficacy of therapy vs surveillance in resected early-stage intermediate to high-risk renal cell carcinoma. METHODS: We performed a systematic literature search using PubMed, EMBASE, and SCOPUS. Keywords such as “renal cell carcinoma”, “adjuvant therapy” and “nephrectomy” were used. In the literature search, 2,711 studies were identified and screened. RESULTS: We included a total of 21 publications. The most common histology seen in trials was clear cell carcinoma. A variety of interventions were reviewed including immunotherapy, medroxyprogesterone acetate, interferon alfa, and tyrosine kinase inhibitors. Most trials did not demonstrate a benefit in relapse-free survival (RPS) or overall survival (OS). Pembrolizumab demonstrated a significant difference in disease recurrence in the KEYNOTE-564 trial although median data was not reached. Blinded independent reviewers identified a benefit in disease-free survival (DFS) with Sunitinib in the S-TRAC trial. CONCLUSION: There was not a clear benefit in using adjuvant therapy broadly for resected locoregional RCC; however, further investigation should be done in the highest-risk group to elucidate potential benefit.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43109762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Hapke, L. Venton, K. Rose, Q. Sheng, Anupama Reddy, Rebecca A. Prather, Angela Jones, W. Rathmell, Scott M. Haak
{"title":"Erratum to: SETD2 Regulates the Methylation of Translation Elongation Factor eEF1A1 in Clear Cell Renal Cell Carcinoma","authors":"R. Hapke, L. Venton, K. Rose, Q. Sheng, Anupama Reddy, Rebecca A. Prather, Angela Jones, W. Rathmell, Scott M. Haak","doi":"10.3233/kca-229010","DOIUrl":"https://doi.org/10.3233/kca-229010","url":null,"abstract":"","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47016617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luke Wang, A. Saidian, Elizabeth Pan, Justine Panian, I. Derweesh, R. McKay
The standard of care for localized renal cell carcinoma (RCC) is radical or partial nephrectomy. Despite complete resection, a subset of patients will develop locoregional recurrence or metastatic disease. Adjuvant immunotherapy has been studied since the 1980 s as the primary method to mitigate tumor recurrence after definitive surgery. We herein discuss published and ongoing clinical trials investigating adjuvant therapy in localized or locoregional RCC.
{"title":"Adjuvant Therapy in Renal Cell Carcinoma: Are we ready for prime time?","authors":"Luke Wang, A. Saidian, Elizabeth Pan, Justine Panian, I. Derweesh, R. McKay","doi":"10.3233/kca-220014","DOIUrl":"https://doi.org/10.3233/kca-220014","url":null,"abstract":"The standard of care for localized renal cell carcinoma (RCC) is radical or partial nephrectomy. Despite complete resection, a subset of patients will develop locoregional recurrence or metastatic disease. Adjuvant immunotherapy has been studied since the 1980 s as the primary method to mitigate tumor recurrence after definitive surgery. We herein discuss published and ongoing clinical trials investigating adjuvant therapy in localized or locoregional RCC.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47635128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: Immune checkpoint inhibitors (ICPIs) are widely used in treating metastatic renal cell carcinoma (RCC). Cytoreductive nephrectomy (CN) forms part of multimodality treatment in advanced disease, however there is no prospective evidence for its use in the ICPI era. Trials of neoadjuvant ICPIs in RCC are underway; understanding the anticipated effect of ICPIs on the primary tumour may help clinical decision making in both localised and advanced settings. METHODS: A systematic search (PubMed, Web of Science, clinicaltrials.gov) of English literature from 2012 to 2022 was performed according to PRISMA guidelines. 2,398 records were identified, 54 were included in the analysis. RESULTS: In the metastatic setting, response in the primary tumour (≥30% reduction in size) is seen in 33–56% of patients treated with dual ICPI or ICPI + VEGFR-TKI. Pathological complete response rates were 14% for patients undergoing CN after a period of ICPI therapy. In the neoadjuvant setting there is a single published trial of VEGFR-TKI + ICPI, 30% of patients had a≥30% reduction in size of the primary. This appears superior to single agent ICPI. Grade 3 adverse event rates are comparable to the metastatic setting. CONCLUSIONS: A period of ICPI combination therapy followed by nephrectomy may be considered for selected patients as a strategy to manage metastatic disease. In the neoadjuvant setting, it is not clear whether ICPI + VEGFR-TKI is superior to VEGFR-TKI alone. There is minimal data on whether either CN after ICPI in metastatic patients, or neoadjuvant ICPI therapy for localised disease, improves long term survival.
背景：免疫检查点抑制剂（ICPI）广泛应用于治疗转移性肾细胞癌（RCC）。细胞减少性肾切除术（CN）是晚期疾病多模式治疗的一部分，但在ICPI时代没有使用它的前瞻性证据。新佐剂ICPI在RCC中的试验正在进行中；了解ICPI对原发性肿瘤的预期影响可能有助于在局部和晚期环境中做出临床决策。方法：根据PRISMA指南，对2012年至2022年的英语文献进行系统检索（PubMed，Web of Science，clinicaltrials.gov）。确定了2398份记录，其中54份被纳入分析。结果：在转移性环境中，33–56%接受双重ICPI或ICPI+VEGFR-TKI治疗的患者对原发性肿瘤有反应（大小缩小≥30%）。在ICPI治疗一段时间后，接受CN的患者的病理完全缓解率为14%。在新佐剂环境中，有一项VEGFR-TKI+ICPI的单一已发表试验，30%的患者原发性肿瘤大小缩小≥30%。这似乎优于单剂ICPI。3级不良事件发生率与转移情况相当。结论：对于选定的患者，可以考虑在肾切除后进行一段时间的ICPI联合治疗，作为治疗转移性疾病的策略。在新佐剂设置中，尚不清楚ICPI+VEGFR-TKI是否优于单独的VEGFR-TKI。关于转移性患者ICPI后的CN，或局部疾病的新辅助ICPI治疗是否能提高长期生存率，目前的数据很少。
{"title":"Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review","authors":"James O. Jones, Will Ince, S. Welsh, G. Stewart","doi":"10.3233/kca-220012","DOIUrl":"https://doi.org/10.3233/kca-220012","url":null,"abstract":"BACKGROUND: Immune checkpoint inhibitors (ICPIs) are widely used in treating metastatic renal cell carcinoma (RCC). Cytoreductive nephrectomy (CN) forms part of multimodality treatment in advanced disease, however there is no prospective evidence for its use in the ICPI era. Trials of neoadjuvant ICPIs in RCC are underway; understanding the anticipated effect of ICPIs on the primary tumour may help clinical decision making in both localised and advanced settings. METHODS: A systematic search (PubMed, Web of Science, clinicaltrials.gov) of English literature from 2012 to 2022 was performed according to PRISMA guidelines. 2,398 records were identified, 54 were included in the analysis. RESULTS: In the metastatic setting, response in the primary tumour (≥30% reduction in size) is seen in 33–56% of patients treated with dual ICPI or ICPI + VEGFR-TKI. Pathological complete response rates were 14% for patients undergoing CN after a period of ICPI therapy. In the neoadjuvant setting there is a single published trial of VEGFR-TKI + ICPI, 30% of patients had a≥30% reduction in size of the primary. This appears superior to single agent ICPI. Grade 3 adverse event rates are comparable to the metastatic setting. CONCLUSIONS: A period of ICPI combination therapy followed by nephrectomy may be considered for selected patients as a strategy to manage metastatic disease. In the neoadjuvant setting, it is not clear whether ICPI + VEGFR-TKI is superior to VEGFR-TKI alone. There is minimal data on whether either CN after ICPI in metastatic patients, or neoadjuvant ICPI therapy for localised disease, improves long term survival.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43019107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Piramide, Dorival M Duarte, D. Amparore, A. Piana, S. De Cillis, G. Volpi, J. Meziere, C. Fiori, F. Porpiglia, E. Checcucci
Background: The employment of 3-dimensional (3D) virtual models of the organs and tumors, obtained from conventional 2-dimensional (2D) imaging (i.e. computed tomography scan and magnetic resonance imaging) have already demonstrated an outstanding potential in urology, especially in renal surgery. Objectives: The aim of this systematic review is to provide an updated focus on the results obtained from the preoperative employment of 3D virtual imaging reconstructions in nephron sparing oncological surgery. Methods: A systematic literature search was conducted in April 2022 using Medline (via PubMed), Embase (via Ovid), Scopus, and Web of Science. The search strategy used PICO criteria and article selection was conducted in accordance with the PRISMA guidelines. The risk of bias and the quality of the articles included were assessed. A dedicated data extraction form was used to collect the data of interest. Results: The initial electronic search identified 471 papers, of which 13 ultimately met the inclusion criteria and were included in the review. 11 studies reported outcomes of virtual models, 2 studies focused on printed 3D models. In these studies, the application of 3D models for preoperative planning has been reported to increase the selective clamping rate and reducing the opening of collecting system, blood loss and loss of renal function. Conclusions: 3D virtual models seem to provide some surgical benefits for preoperative planning especially for complex renal masses. In the next future the continuous evolution of this technology may further increase its field of application and its potential clinical benefit.
背景：从传统的二维（2D）成像（即计算机断层扫描和磁共振成像）中获得的器官和肿瘤的三维（3D）虚拟模型的应用已经在泌尿外科，特别是肾脏外科中显示出突出的潜力。目的：本系统综述的目的是对保留肾单位肿瘤手术中术前使用3D虚拟成像重建获得的结果进行最新的关注。方法：2022年4月，使用Medline（通过PubMed）、Embase（通过Ovid）、Scopus和Web of Science进行系统的文献检索。搜索策略使用PICO标准，文章选择根据PRISMA指南进行。评估了偏倚的风险和文章的质量。使用了专门的数据提取表格来收集感兴趣的数据。结果：最初的电子搜索确定了471篇论文，其中13篇最终符合入选标准并被纳入审查。11项研究报告了虚拟模型的结果，2项研究侧重于打印的3D模型。在这些研究中，据报道，3D模型在术前计划中的应用可以提高选择性夹紧率，减少采集系统的开放、失血和肾功能丧失。结论：三维虚拟模型似乎为术前计划提供了一些手术益处，尤其是对于复杂的肾脏肿块。在未来，这项技术的不断发展可能会进一步扩大其应用领域和潜在的临床效益。
{"title":"Systematic Review of Comparative Studies of 3D Models for Preoperative Planning in Minimally Invasive Partial Nephrectomy","authors":"F. Piramide, Dorival M Duarte, D. Amparore, A. Piana, S. De Cillis, G. Volpi, J. Meziere, C. Fiori, F. Porpiglia, E. Checcucci","doi":"10.3233/kca-220008","DOIUrl":"https://doi.org/10.3233/kca-220008","url":null,"abstract":"Background: The employment of 3-dimensional (3D) virtual models of the organs and tumors, obtained from conventional 2-dimensional (2D) imaging (i.e. computed tomography scan and magnetic resonance imaging) have already demonstrated an outstanding potential in urology, especially in renal surgery. Objectives: The aim of this systematic review is to provide an updated focus on the results obtained from the preoperative employment of 3D virtual imaging reconstructions in nephron sparing oncological surgery. Methods: A systematic literature search was conducted in April 2022 using Medline (via PubMed), Embase (via Ovid), Scopus, and Web of Science. The search strategy used PICO criteria and article selection was conducted in accordance with the PRISMA guidelines. The risk of bias and the quality of the articles included were assessed. A dedicated data extraction form was used to collect the data of interest. Results: The initial electronic search identified 471 papers, of which 13 ultimately met the inclusion criteria and were included in the review. 11 studies reported outcomes of virtual models, 2 studies focused on printed 3D models. In these studies, the application of 3D models for preoperative planning has been reported to increase the selective clamping rate and reducing the opening of collecting system, blood loss and loss of renal function. Conclusions: 3D virtual models seem to provide some surgical benefits for preoperative planning especially for complex renal masses. In the next future the continuous evolution of this technology may further increase its field of application and its potential clinical benefit.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49406466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Memoriam: Nicholas J. Vogelzang MD","authors":"P. Lara, Peter Mulders","doi":"10.3233/kca-229005","DOIUrl":"https://doi.org/10.3233/kca-229005","url":null,"abstract":"","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44256541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Clinical Trials Corner of Kidney Cancer highlights planned or ongoing high-impact studies in renal cell 8 carcinoma (RCC). In this issue, we highlight the PAPMET-2 study, an important Phase II study evaluating the 9 treatment of patients with advanced papillary renal cell carcinoma (pRCC). 10 In future, if you feel that you would like to draw attention to a specific trial, A Phase II Randomized Trial of Cabozantinib (NSC#761968) With or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma Study Design: This study enrolls patients with metastatic histologically confirmed pRCC (either Type 1 or Type 34 2) with radiographically measurable disease who are ICI- and cabozantinib-na¨ıve and who have been treated 35 with one or fewer targeted therapies for pRCC. Following enrollment, patients are randomized to receive either 36 60 mg of cabozantinib orally or 60 mg of cabozantinib orally plus atezolizumab 1200 mg intravenously every 3 37 weeks, until the time of disease progression or unacceptable toxicity. 38 Endpoints: The primary endpoint of this trial is progression-free survival (PFS). Key secondary outcomes include 39 overall survival (OS), objective response rate (ORR), and quantitative & qualitative adverse events observed in 40 each treatment arm. 41 as trials combining nivolumab with cabozantinib have treated patients with 40 mg of cabozantinib daily; in this study, the dose will be 60 mg in both arms. Thus, tolerance of this dose level in combination with ICI will be an important observation. The strength of this study is its uniformity in enrolling patients with pRCC, which is important as retrospective studies have reflected heterogeneity in outcomes based on histologic subtypes undoubtedly in part due to differences in responses to currently available therapies.
{"title":"Clinical Trials Corner: Optimizing Papillary Renal Cell Carcinoma Care","authors":"M. Parikh","doi":"10.3233/kca-229004","DOIUrl":"https://doi.org/10.3233/kca-229004","url":null,"abstract":"The Clinical Trials Corner of Kidney Cancer highlights planned or ongoing high-impact studies in renal cell 8 carcinoma (RCC). In this issue, we highlight the PAPMET-2 study, an important Phase II study evaluating the 9 treatment of patients with advanced papillary renal cell carcinoma (pRCC). 10 In future, if you feel that you would like to draw attention to a specific trial, A Phase II Randomized Trial of Cabozantinib (NSC#761968) With or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma Study Design: This study enrolls patients with metastatic histologically confirmed pRCC (either Type 1 or Type 34 2) with radiographically measurable disease who are ICI- and cabozantinib-na¨ıve and who have been treated 35 with one or fewer targeted therapies for pRCC. Following enrollment, patients are randomized to receive either 36 60 mg of cabozantinib orally or 60 mg of cabozantinib orally plus atezolizumab 1200 mg intravenously every 3 37 weeks, until the time of disease progression or unacceptable toxicity. 38 Endpoints: The primary endpoint of this trial is progression-free survival (PFS). Key secondary outcomes include 39 overall survival (OS), objective response rate (ORR), and quantitative & qualitative adverse events observed in 40 each treatment arm. 41 as trials combining nivolumab with cabozantinib have treated patients with 40 mg of cabozantinib daily; in this study, the dose will be 60 mg in both arms. Thus, tolerance of this dose level in combination with ICI will be an important observation. The strength of this study is its uniformity in enrolling patients with pRCC, which is important as retrospective studies have reflected heterogeneity in outcomes based on histologic subtypes undoubtedly in part due to differences in responses to currently available therapies.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":"1 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41399007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：